Dear Greg, you started as CEO of Epigenomics AG since July 2016, as we look back now 10 months to your first official statement about Epigenomics (Q2 conerfence call) stated below.. What do you think about your goals, purposes and implementation of tasks?
Unfortunately, I couldn't listen your statements at the last shareholder meeting. But it's obsious you are not following your inital goals, the company's benefits and its shareholders. Not even a substential explanation for your change of mind. Only using the the communication ability of a horror scenario. But think, many shareholders know Epigenomics longer than you and your way is probably only benefital for you.
You recognize shareholders here stand together and defend its equity capital. Please stop talking about shareholders' benefit. These shareholders capitalized Epigenomics for many many years taking part in increases of capital stock, remained faithful after study and approval failures and hold firm in times of high volatilities. Maybe it's romantic, you would say. But today for you only one chance exist, for the shareholders there are many more.. We will keep defending!
Now also agains a company's CEO who is not operating the interests of the companys' shareholders. Sad story for you, after one year. Take the moment and think back, only 12 months, spoken words, promises - I think we both know the answer, but you have to sleep with this responsibility! Poor boy!
Good luck, Jamannn! Its my pleasure now to hand over to the companys CEO, Greg Hamilton. Greg, please go ahead and read your statements again!
8 June 2017, Offer document published for the voluntary public takeover offer for Epigenomics AG:
Greg Hamilton, CEO of Epigenomics: "The takeover offer is in the best interests of Epigenomics and its shareholders. The transaction gives us access to the necessary capital and resources in order to successfully market our products in the future and to develop innovative cancer-detection tests. It enables all shareholders to capitalize today on the value potential of Epigenomics in view of the existing risks." (Source: http://www.finanzen.net/nachricht/aktien/...s-epigenomics-ag-5518682)
10 August 2016, Epigenomics AG Q2 2016 Earnings Conference Call
"My strategic priorities for Epigenomics are first to maximize shareholder value. I believe, Epi is an incredibly valuable company. It is truly pioneering the liquid biopsy market. For us to generate the value potential in front of us, we must optimize the positioning of the product and drive market adoption of Epi proColon. The key to this will be reimbursement, key customer adoption, medical education and global market opportunities. In addition, we will continue forward our new development. We have a robust IP portfolio, which capitalizes on our proprietary methylation technology. As we look over the next 12 to 18 months, we need to fuel market penetration and adoption. This can only happen if Epi is resourced appropriately to take advantage of the significant market opportunity in front of us. As such, Epigenomics disclosed, we had confidentially submitted a Draft Registration Statement on Form F-1 to the United States Securities and Exchange Commission for a potential U.S. public offering of American Depositary Shares." (Source: https://seekingalpha.com/article/...results-earnings-call-transcript) |
Thread abonnieren
